Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Express News | Johnson & Johnson : HSBC Raises Target Price to $180 From $174
Johnson & Johnson (JNJ.US) antibody therapy receives FDA approval again.
Previously, Johnson & Johnson (JNJ.US) announced that the US FDA has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients.
Unpacking the Latest Options Trading Trends in Johnson & Johnson
JNJ Submits Application to EMA for Nipocalimab for Generalized Myasthenia Gravis
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}